Article abstract-Cognitive and functional outcomes are of primary interest in the design of efficacy trials in HIV-associated cognitive impairment. In a longitudinal cohort study, weak associations were found between measures of cognitive performance and commonly used measures of daily functioning (mostly self-report measures) in HIV-infected individuals. Modifications of current functional scales or new functional instruments are needed to assess the clinical relevance of cognitive changes in clinical trials of HIV-associated cognitive impairment.
Cognitive impairment is a common sequela of HIV-1 infection 1 that continues to exist despite the current use of potent antiretroviral therapy. Clinical trials in HIV-associated cognitive impairment have been largely safety and tolerability studies, relatively short in duration. [2] [3] [4] However, as we move from these early phase studies to larger efficacy trials, cognitive and functional outcomes are of primary interest. Unfortunately, there are no available measures of function specifically designed to assess performance in HIV-infected subjects with cognitive impairment. Using data from the Dana cohort, 5 we investigated whether or not commonly used functional measures were associated with cognitive performance.
Design and method. The characteristics of the Dana cohort have been previously described. 5 Based on a modification of the American Academy of Neurology (AAN) recommendations 5 and previous clinical trials in HIVassociated cognitive impairment, 4 we defined mild cognitive impairment as performance that was 2 SD below the appropriate means on one test (which could not be timed gait) or 1 SD below the mean on at least two tests. Subjects having no test scores 2 SD below the mean and no more than one test score 1 SD below the mean were classified as not impaired (some of these subjects might have met AAN criteria for minor cognitive/motor disorder 5 ) . In this study, we classified the remaining subjects based only on the number of tests on which scores were 2 SD below the mean as moderately impaired (two or three tests 2 SD below thee mean) or as severely impaired (four or more tests 2 SD below the mean). It was felt that a test 2 SD below the mean would represent a definite abnormal result and that if 50% (four) or more of the neuropsychological tests were 2 SD below the mean the cognitive performance would be severely impaired.
Average z scores were created from the neuropsychological test battery with the aid of a principal component factor analysis using varimax rotation. 9 In addition, the Center for Epidemiologic Studies-Depression Scale (CES-D) was used to assess mood.
A detailed description of the statistical methods used can be found on the web site. Brief descriptions follow in Results and the tables.
Results. Demographic and clinical characteristics of the participants at baseline are shown in table 1. Functional performance tended to decline with increasing degree of cognitive impairment at baseline (table 2), in particular with regard to Role Function, Physical Function, and Karnofsky Performance Scale score. These differences were attenuated after adjustment for other baseline covariates. The percentages of subjects demonstrating an IADL deficit were as follows: unimpaired, 40%; mild, 41%; moderate, 34%; severe, 56%. The percentages of subjects demonstrating an SMADL deficit were as follows: unimpaired, 10%; mild, 9%; moderate, 12%; severe, 20%.
Of the 270 subjects included in the baseline analyses, 138 had a 1-year follow-up visit, 102 did not return for the 1-year visit (46 due to death, 31 due to loss to follow-up, 11 due to withdrawal of consent, 11 for other reasons, and three for unknown reasons), and 30 were enrolled into the study too late to have a 1-year follow-up visit. The dropout rates before 1 year were the following: unimpaired, 36%; mild, 39%; moderate, 53%; severe, 52%. As expected, those who dropped out before 1 year tended to have more advanced HIV infection and lower Physical Function scores than those who had a 1-year visit (additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for this issue to find the title link for this article). In terms of cognitive function, the two groups tended to differ only in average Psychomotor Speed z scores ( p ϭ 0.07; additional information related to this article can be found on the Neurology Web site) .
Cognitive and functional performance tended to be either stable or improved after 1 year of follow-up (table 3) . Seventy percent (70%) of subjects changed by at most 1 point on the IADL scale, and 87% of subjects did not change at all on the SMADL scale. The improvement in Attention/Memory z scores tended to be more prominent for the groups with mild/moderate cognitive impairment, and the improvement in the Executive Function and Psychomotor Speed z scores tended to be more prominent for the groups with moderate/severe cognitive impairment. The improvement in Role Function was consistent across the cognitive impairment groups (additional information related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for this issue to find the title link for this article).
Overall, the correlations between the 1-year changes in function (Karnofsky Performance Scale, Role Function, Physical Function) and the 1-year changes in cognitive performance (domain z scores) were weak, with only one correlation (between Karnofsky Performance Scale score and the Psychomotor Speed z score, r ϭ 0.26, p ϭ 0.003) being Ͼ0.20. Within the subgroup of subjects with mild cognitive impairment, the partial correlations (adjusted for CES-D, CD4 count, and hemoglobin) between the change in Executive Function z score and changes in the functional tests were as follows: 0.44 (p ϭ 0.007) for Karnofsky Performance Scale score, 0.33 (p ϭ 0.05) for Role Function, and 0.37 (p ϭ 0.02) for Physical Function. For subjects with moderate cognitive impairment, significant partial correlations were observed between the change in Karnofsky Performance Scale score and both the Attention/ Memory z score (r ϭ 0.52, p ϭ 0.009) and the Psychomotor Speed z score (r ϭ 0.54, p ϭ 0.01).
Discussion. In the current study, we investigated the relationship between the degree of HIVassociated cognitive impairment, as defined by neuropsychological test performance, and commonly used measures of daily function. Our results show that at baseline, IADL 6 and SMADL 7 had the weakest relationships with cognitive performance. The other three measures, Role Function, 8 Physical Function, 8 and the Karnofsky Performance Scale, 9 indicated that functional impairment tended to be present only in patients with severe cognitive dysfunction. However, when other factors such as age, education, mood, and immune function were taken into account, none of the functional measures showed a significant relationship with cognitive performance (see table 2) .
A 12-month evaluation showed a weak association between changes in functional measures and changes in cognition. Conversely, the cognitive subgroup analyses showed some significant but nonuniform relationships between changes in cognition and changes in functional measures. For example, the Karnofsky Performance Scale was the functional measure that correlated best with Executive Function (mild cognitive impairment subgroup) and with Attention/Memory and Psychomotor Speed (moderate cognitive impairment subgroup).
The five functional measures used in this study, with the exception of the Karnofsky scale, are self--report measures. It may be anticipated that subjects with more severe cognitive impairment may not realize the extent of their functional decline. This may explain in part the results of the cognitive subgroup analyses, suggesting a better correlation between changes in some cognitive domains and changes in the Karnofsky score (scale scored by physician or nurse). Conversely, the premorbid functional status probably influenced the subject assessment of functional changes.
The longitudinal analyses were limited in part by an attrition of 42.5% at 1 year. The observed cognitive improvement may be a spurious result that could be explained by an enrichment of the cohort of subjects with better cognitive performance after the withdrawal of those with worse performance. Also, regression to mean may be responsible for the improvement. This questionable cognitive improvement may make it difficult to specify a reasonable effect size to try to detect when determining the appropriate sample size for a clinical trial.
Enrolling into trials HIV subjects with cognitive impairment based on neuropsychological test scores rather than the definition of dementia offers some advantages. Dementia, by definition, requires loss of function. Unfortunately, attribution of loss of function to cognitive impairment is a difficult task when applied to a systemic disease such as HIV infection. Furthermore, dementia scales may be prone to substantial variability. 10 In addition, subjects in earlier stages of cognitive impairment may be more likely to respond to therapy. Neuropsychological test batteries are well standardized, thus less prone to subjective interpretation, and can be easily used in multicenter studies. However, modification of current functional scales or new instruments that correlate better with cognitive performance are needed to assess the clinical relevance of impairment (and improvement) on neuropsychological tests. 
